April 17, 2013 - CML- Living with a Chronic Disease
Date: April 17, 2013
Time: 1:00 p.m. - 2:00 p.m. ET
View: Program Slides | Diapositivas (Spanish program slides)
Read: CML News Links (English and Spanish) | Transcript
Listen: Presentation | Q&A Session | Presentación y sesión de preguntas (Spanish audio) | Sesión de preguntas extendido (Spanish extended Q&A)
Access: Virtual Lecture
- Current treatment options for CML patients
- CML therapies
- Key elements of monitoring response to CML treatment
- The role of clinical trials in the advancement of CML treatment
- Quality of life issues for patients living with CML
- Communication touch points among patients and healthcare providers
Jorge Cortes, MD
D.B. Lane Cancer Research Distinguished Professor for Leukemia Research
Deputy Chairman, Section Chief of AML & CML
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Questions Asked by the CML Community
- Should a patient discontinue taking dasatinb (Sprycel®) after eight years due to memory issues?
- Have there been any studies on imatinib (Gleevec®) and its implication on cognitive development?
- What is the percent of CML patients now that need to have a stem cell transplant?
- Can you talk about fertility in male patients on Sprycel?
- If Gleevec stopped working after three years, would the next treatment option be to start taking ponatinib (IclusigTM) and also try a stem cell program?
- If a younger person needs to take nilotinib (Tasigna®) for many years, is there concern about organ problems happening in the future?
- Can you participate in a clinical trial if your disease is undetectable?
- What kinds of options exist to monitor CML if the PCR tests are not available?